EUVIMEDEUVIMED entdecken
LeserbriefOpen Access · CC BY 4.0

Targeting ARPC1B + Cancer Stem Cells to Sensitise Pancreatic Cancer to Gemcitabine Treatment

Yang Wu iD, Jianpeng Zhang iD, Weixiong Zhu iD, Xinrui Zhu, Yi Liu, Xin Wang, Tianyu Zhao, Chun Zhang, Zili Zhang, Wenjie Shi iD, Run Shi, Zhaokai Zhou iD und 1 weitere

Cell Proliferation · 2025

DOI: 10.1111/cpr.70125 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Cell Proliferation, 2025. Verfasst von Yang Wu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Deoxycytidine, Neoplastic Stem Cells, Pancreatic Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Jiangsu Province "Double-Creation Doctorate" Talent Program, Jiangsu Provincial Hospital of Traditional Chinese Medicine Excellent Doctoral Cultivation Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DeoxycytidineNeoplastic Stem CellsPancreatic NeoplasmsGemcitabineHumansAnimalsMiceDrug Resistance, NeoplasmCell Line, TumorXenograft Model Antitumor AssaysMice, NudeAntimetabolites, AntineoplasticMolecular Docking Simulation

Substanzen

GemcitabineDeoxycytidineAntimetabolites, Antineoplastic

Autor:innen und Institutionen

  • Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Department of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • The Second Clinical Medical College, Lanzhou University, Lanzhou, China.
  • Department of Hepatobiliary and Pancreatic Surgery, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.
  • Department of Oncology, The Second Hospital of Dalian Medical University, Dalian, China.
  • Department of Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, China.

ORCID-Profile: Yang Wu, Jianpeng Zhang, Weixiong Zhu, Wenjie Shi, Zhaokai Zhou

Förderung

  • National Natural Science Foundation of China
  • Jiangsu Province "Double-Creation Doctorate" Talent Program
  • Jiangsu Provincial Hospital of Traditional Chinese Medicine Excellent Doctoral Cultivation Program
  • Jiangsu Provincial Health Commission Medical Research Project
  • Science and Technology Innovation Project for Nanjing Overseas Chinese
  • The Incubation Program of National Natural Science Foundation of Jiangsu Provincial People's Hospital
  • Jiangsu Funding Program for Excellent Postdoctoral Talent
  • Postdoctoral Fellowship Program of CPSF

Zitieren

APA

Wu, Y., Zhang, J., Zhu, W., Zhu, X., Liu, Y., Wang, X., Zhao, T., Zhang, C., Zhang, Z., Shi, W., Shi, R., Zhou, Z., & Xu, S. (2025). Targeting ARPC1B + Cancer Stem Cells to Sensitise Pancreatic Cancer to Gemcitabine Treatment. Cell Proliferation. https://doi.org/10.1111/cpr.70125

Vancouver

Wu Y, Zhang J, Zhu W, Zhu X, Liu Y, Wang X, et al. Targeting ARPC1B + Cancer Stem Cells to Sensitise Pancreatic Cancer to Gemcitabine Treatment. Cell Proliferation. 2025. doi:10.1111/cpr.70125

BibTeX
@article{Wu2025,
  author = {Wu, Yang and Zhang, Jianpeng and Zhu, Weixiong and Zhu, Xinrui and Liu, Yi and Wang, Xin and Zhao, Tianyu and Zhang, Chun and Zhang, Zili and Shi, Wenjie and Shi, Run and Zhou, Zhaokai and Xu, Shaohui},
  title = {Targeting ARPC1B + Cancer Stem Cells to Sensitise Pancreatic Cancer to Gemcitabine Treatment},
  journal = {Cell Proliferation},
  year = {2025},
  doi = {10.1111/cpr.70125}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche